In January 2022, Arterial Network conducted an exclusive interview with our company. Professor Wang Jianxun, the chief scientist, introduced the core team members and main service modules of Junhou Biotech. At present, Junhou Biology has built and put into production a 1000m2 GMP workshop, which is compared with other genetic engineering cellular immunotherapy projects2022年1月，动脉网对我司进行了专访，首席科学家王建勋教授介绍了君厚生物的核心团队成员及主要服务模块。目前君厚生物已建成并投入生产1000m2 GMP级生产车间，相比于其他基因工程细胞免疫治疗项目

With the scientific research still at the laboratory level, Junhou Biotech has been able to produce standardized clinical standards. Regarding the future market development and the company's prospects, Professor Wang Jianxun said that there is no mature benchmarking enterprise in China at present. Junhou Bio has more than three years of technology leadership and at least more than one generation of product generation leadership, and is expected to occupy more than 50% of the market in this field. Junhou Bio is equivalent to a water seller in the cell therapy industry, providing a steady stream of power for the middle and downstream companies trying to dig gold.仍停留在实验室水平的科学研究，君厚生物已经具备规范化的临床级标准的生产能力。对于未来市场发展及公司前景，王建勋教授表示，目前国内还没有成熟的对标企业，君厚生物拥有3年以上的技术领先和至少1代以上的产品代差领先，预计能占领该领域50%以上的市场。君厚生物相当于细胞治疗行业的卖水人，为试图掘金的中下游公司提供了源源不断的动力。